Siemens filed the initial mdr 1219913-2020-00624 on december 14, 2020.January 07, 2021 additional information: siemens healthcare diagnostics has investigated.The investigation determined that although non-reproducible false reactive results were observed, results indicate the negative percent agreement confidence interval of the kit lots evaluated overlap the confidence interval in the ifu; therefore the atellica im sars-cov-2 total (cov2t) lot 001 is performing within claims and a change in performance has not been confirmed.No product non-conformance has been identified.No further evaluation of the device is required.
|
The quality control (qc) was in range.After the initial result was reported, the sample was stored inside the rsm module on the aptio track overnight.The sample was retrieved from storage the next morning to begin the lot to lot correlation study.There had been no hardware issues with the storage module, so it is assumed the sample was at refrigerated temperature when run for this purpose.The sample then sat on the sample handler for approximately 1 hour when it was run on lot 001 for 4 additional replicates.The ifu states in the limitations section: "this assay should not be used to diagnose or exclude acute infection.Results are not intended to be used as the sole basis for patient management decisions.Test results should be interpreted in conjunction with clinical observations, patient history, epidemiological information, and other laboratory findings.A reactive test result does not exclude past or present infection by other coronaviruses, such as sars-cov-1, mers-cov, hku1, 229e, nl63, or oc43." a false positive/reactive result would not be used in isolation and would be correlated with clinical history.Additional laboratory testing would be used to determine specific antibody presence.Although there is no potential for serious injury in this case, an mdr will be reported to the fda as a requirement of the emergency use authorization (eua).Siemens healthcare diagnostics is investigating.
|